全球血栓药物市场 – 行业趋势及 2031 年预测

血栓药物市场分析及规模

在创新型抗凝剂和溶栓剂的推动下，血栓药物市场正在快速发展。药物研发人工智能和个性化医疗等最新技术正在提高治疗效果。由于意识的提高、研发投入的增加以及血栓性疾病的流行，市场正在增长。洞察揭示了更安全、更有效的治疗方法的趋势。                                

2023 年全球血栓药物市场规模为 112.4 亿美元，预计到 2031 年将达到 217.3 亿美元，预测期内（2024 年至 2031 年）的复合年增长率为 8.59%。这表明市场价值。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分

Market Definition

A thrombosis drug, also known as an anticoagulant or blood thinner, is a medication that prevents blood clots (thrombosis) from forming or growing. These drugs include warfarin, heparin, and newer agents such as rivaroxaban and apixaban. They are used to treat or prevent conditions such as deep vein thrombosis, pulmonary embolism, and stroke in atrial fibrillation patients.            

Thrombosis Drug Market Dynamics

Drivers

• Rising Prevalence of Cardiovascular Diseases

The rising prevalence of cardiovascular diseases, such as heart attacks and strokes, which often lead to thrombosis, drives the thrombosis drug market. For instance, the American Heart Association reports an increasing number of stroke cases each year, necessitating the development and use of effective thrombosis treatments. This growing demand for preventative and therapeutic drugs significantly boosts market growth, as more patients require ongoing management of their conditions.

• Increasing Obesity Rates

Increasing obesity rates significantly drive the thrombosis drug market, as obesity is a major risk factor for thrombosis. For instance, the Centers for Disease Control and Prevention (CDC) reports a consistent rise in obesity rates in the U.S., with over 40% of adults classified as obese in recent years. This growing population at risk elevates the demand for effective thrombosis treatments, thereby expanding the market.

Opportunities

• Enhanced Diagnostic Techniques

Improved diagnostic techniques for thrombosis, such as ultrasound imaging and D-dimer testing, facilitate early and precise detection of blood clots. For instance, advanced imaging modalities such as CT angiography allow clinicians to identify thrombosis in pulmonary arteries swiftly. This early diagnosis not only ensures prompt initiation of thrombosis treatment but also boosts the demand for effective drugs. Consequently, healthcare providers and patients benefit from improved outcomes, driving growth in the thrombosis drug market.

• Aging Population Create Demand

The aging global population significantly drives the thrombosis drug market. As people age, the risk of developing thrombosis rises due to factors such as decreased mobility and higher prevalence of conditions such as atrial fibrillation. For instance, in countries such as Japan and Italy, where a substantial portion of the population is elderly, the demand for effective thrombosis treatments has surged, bolstering market growth and encouraging pharmaceutical advancements.

Restraints/Challenges

• Ethical and Legal Considerations in Genetic Testing

Ethical and legal concerns regarding genetic testing and personalized medicine create uncertainty, deterring both individuals and healthcare providers from embracing these diagnostic approaches. This hesitation limits market growth for autoimmune disease diagnosis due to compromised patient privacy, inadequate consent processes, and the potential misuse of genetic information. 

• High Cost of Diagnostic Tests

The high cost of advanced diagnostic tests for autoimmune diseases restricts accessibility in resource-constrained settings, hampering market growth. This financial barrier hinders widespread adoption, limiting the market's reach and preventing many individuals from undergoing crucial diagnostic procedures, contributing to a substantial gap in autoimmune disease diagnosis and management. 

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In February 2023, Bayer initiated patient enrollment in its OCEANIC clinical trial program. The program assesses asundexian (BAY2433334), an oral Factor XIa inhibitor, for atrial fibrillation (AF) and non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA) patients. This investigational drug aims to mitigate thrombotic risks in these conditions, potentially offering new therapeutic avenues
• In July 2022, Anthos Therapeutics' abelacimab received FDA fast-track designation for treating cancer-related thrombosis. This designation accelerates the drug's regulatory review process, recognizing its potential in addressing thrombotic complications associated with cancer treatment, highlighting a significant step towards enhancing thrombosis management in oncology patients

Thrombosis Drug Market Scope

市场根据药物类别、疾病类型、给药途径和分销渠道进行细分。这些细分市场之间的增长情况将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

药物类别

• Xa因子抑制剂
• 肝素
• P2Y12 血小板抑制剂
• 其他

 疾病类型

• 肺栓塞
• 心房颤动
• 深静脉血栓形成
• 其他

 分销渠道

• 医院药房
• 零售药店
• 网上药店

 给药途径

• 口服
• 肠外

血栓药物市场区域分析/见解

对市场进行分析，并按上述国家、药物类别、疾病类型、给药途径和分销渠道提供市场规模见解和趋势。

市场报告涉及的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区（APAC）的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲（MEA）的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

预计亚太地区血栓药物市场将以最高的增长率增长，这得益于人们对深静脉血栓等疾病的认识不断提高和患病率不断上升，从而推动该地区对深静脉血栓有效治疗和药物的需求增加。

北美预计将主导血栓药物市场，因为该地区心血管疾病发病率高、老年人口众多、先进技术广泛采用，从而促进治疗方案的强劲增长和创新。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

医疗保健基础设施增长安装基础和新技术渗透

该市场还为您提供每个国家/地区资本设备医疗支出增长、市场上不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对市场的影响的详细市场分析。数据适用于 2016-2021 年的历史时期。

竞争格局和血栓药物市场份额分析

市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

市场上的一些主要参与者包括：

• 阿斯利康（英国）
• 勃林格殷格翰国际有限公司 (德国)
• 强生服务公司（美国）
• 赛诺菲（法国）
• 阿斯彭控股 (南非)
• 拜耳公司（德国）
• 百时美施贵宝（美国）
• 辉瑞公司（美国）
• 百特（美国）
• 葛兰素史克公司 (英国)
• 第一三共株式会社（日本）
• Grifols, SA（西班牙）
• Viatris Inc.（美国）
• Biogen（美国）
• Vasudha Pharma（印度）
• GoodRx, Inc.（美国）
• ITALFARMACO SpA（意大利）

SKU-59730